InvestorsHub Logo
Followers 91
Posts 5592
Boards Moderated 0
Alias Born 06/05/2008

Re: Sunofwolf post# 6814

Wednesday, 09/27/2017 10:32:20 AM

Wednesday, September 27, 2017 10:32:20 AM

Post# of 8172
BUY THE DIPS, I am,

just on the concluding paragraph of the press release, the earnings potential of CLR 131 tripled:

"...On April 27, 2017, the company reported that preclinical experiments providing multiple doses (two or three doses) of CLR 131 resulted in a statistically significant benefit in survival and tumor burden reduction compared to a single dose regimen. Therefore the company has now elected to advance with a multi-dose regimen, which may provide patients with enhanced clinical benefits and treatment outcomes."

These cohort 4 patients were in bad shape and ready to expire- CLR 131 saved them. IMHO
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CLRB News